<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980236</url>
  </required_header>
  <id_info>
    <org_study_id>CP04573.A</org_study_id>
    <nct_id>NCT03980236</nct_id>
  </id_info>
  <brief_title>Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]</brief_title>
  <acronym>LISA Pilot</acronym>
  <official_title>Feasibility of Using the Insulia App in an Integrated Platform With Livongo for Patients With Type 2 Diabetes Treated With Basal Insulin [Pilot Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Livongo Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Voluntis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evidation Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Livongo Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective,&#xD;
      interventional study. The purpose of this pilot study is to evaluate the feasibility of using&#xD;
      the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This&#xD;
      will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control&#xD;
      for these individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Did not achieve enrollment goal&#xD;
  </why_stopped>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in A1c from baseline to 12 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Type 2 Diabetes Treated With Insulin</condition>
  <arm_group>
    <arm_group_label>Livongo-Insulia Study App Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Livongo-Insulia Study App</intervention_name>
    <description>Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.</description>
    <arm_group_label>Livongo-Insulia Study App Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Lives in the U.S.&#xD;
&#xD;
          -  Able to speak, read and write in English&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes&#xD;
&#xD;
          -  Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo,&#xD;
             Basaglar, Tresiba U-100) and taking 1 injection per day&#xD;
&#xD;
          -  Takes a daily dose ≤ 0.75 units/kg&#xD;
&#xD;
          -  Estimated A1c ≥ 8% (based on existing Livongo data)&#xD;
&#xD;
          -  Has been enrolled in Livongo for at least 12 weeks&#xD;
&#xD;
          -  Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS&#xD;
             8 or newer)&#xD;
&#xD;
          -  Willing to complete study questionnaires&#xD;
&#xD;
          -  Willing to complete at-home A1c kits&#xD;
&#xD;
          -  Willing to check before breakfast blood glucose at least once per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes&#xD;
&#xD;
          -  Currently using a long-acting basal insulin analog that is not supported by Insulia&#xD;
&#xD;
          -  Currently using rapid-acting, short-acting, or intermediate-acting or premixed&#xD;
             insulins&#xD;
&#xD;
          -  Currently pregnant or planning pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bimal Shah, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Livongo Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Livongo</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Livongo Health</investigator_affiliation>
    <investigator_full_name>Bimal Shah, MD</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

